203 results about "Type ii diabetes" patented technology

The invention discloses bullfrog skin-derived peptide LGPQR and a purification method and application thereof.The molecular weight of the bullfrog skin-derived peptide LGPQR is 570.34 Da, and the amino acid sequence of the bullfrog skin-derived peptide LGPQR is shown as SEQ ID NO.1. The bullfrog skin-derived peptide LGPQR is obtained by extracting bullfrog skin enzymatic hydrolysate through an enzymolysis means to construct a polypeptide library, then screening the polypeptide library through computer-aided screening, and then evaluating the screened peptide fragments so as to be optimal. Finally, the purified bullfrog skin source peptide LGPQR is obtained. According to the bullfrog skin-derived peptide LGPQR as well as the purification method and the application thereof, the bullfrog skin-derived peptide LGPQR has relatively good functions of reducing blood sugar and resisting oxidation, has application potential of type II diabetes medicines, and is safe and free of toxic and side effects. The amino acid sequence is short, the operability is high, and the social popularization and application value is good.

The invention relates to ackermania muciniphila Akk21 with hypoglycemic capacity and application, a product and a method thereof, and belongs to the technical field of microorganisms. The invention provides an ackermania muciniphila strain Akk21 with a blood sugar reducing capability. The preservation number of the ackermania muciniphila strain Akk21 is CCTCC (China Center for Type Culture Collection) NO: M 20242779. The invention also provides hypoglycemic drugs, functional food for promoting lead excretion, health care products and a method for preventing and treating lead / arsenic pollution based on the strain Akk21. The Ackermania muciniphila Akk21 has excellent lead and arsenic tolerance and hypoglycemic capacity, can effectively reduce the blood lipid level of mice with type II diabetes, has a remarkable reduction effect on inflammation of the whole body of the mice, and can remarkably reduce the number of harmful flora in the intestinal tract by increasing the abundance of effective flora in the intestinal tract, so that the content of the harmful flora in the intestinal tract is reduced, and the content of the harmful flora in the intestinal tract is reduced. The species diversity and abundance of intestinal flora are improved.

The invention provides camel milk active peptide and application thereof in preparation of drugs and edible products for treating and / or preventing diabetes mellitus. Two polypeptide compounds are obtained from papain enzymolysis products of fresh camel milk. Bioactivity evaluation shows that the polypeptide compound has remarkable protein tyrosine phospholipase 1B (PTP1B) inhibitory activity, can enhance insulin receptor sensitivity and promote hepatocyte glucose uptake, has patent medicine potential in the aspect of treating type II diabetes, and can be used for preparing medicines for treating type II diabetes. And a new material basis is provided for developing innovative medicines for treating type II diabetes and developing innovative PTP1B inhibitor hypoglycemic medicines.

The invention discloses bullfrog skin-derived peptide and a purification method and application thereof.The molecular weight of the bullfrog skin-derived peptide is 1035.52 Da, and the amino acid sequence of the bullfrog skin-derived peptide is shown as SEQ ID NO.1. The bullfrog skin-derived peptide is extracted through an enzymolysis means to construct a polypeptide library, then the polypeptide library is screened through computer-aided screening, then screened peptide fragments are evaluated so as to be optimized, and the bullfrog skin-derived peptide is obtained. And finally obtaining the purified bullfrog skin source peptide. According to the bullfrog skin source peptide and the purification method and application thereof, the bullfrog skin source peptide has good blood sugar reducing and oxidation resisting functions, has the application potential of type II diabetes mellitus drugs, and is safe and free of toxic and side effects. The amino acid sequence is short, the operability is high, and the social popularization and application value is good.

The invention discloses a diabetic cardiomyopathy clinical prediction model, an establishment method and application thereof. The method includes the steps that clinical data of type II diabetes patients meeting the containing and discharging standard are collected based on public health data and processed, a random forest RF prediction model is established, the random forest RF prediction model is trained and evaluated to finally establish the random forest RF prediction model, the model accuracy is 0.889, the sensitivity is 0.896, the specificity is 0.880, and the recall rate is 0.896. The model has higher prediction accuracy and robustness, and can be used for an intuitive and convenient webpage calculator for early diagnosis of the diabetic cardiomyopathy, so that a clinician can easily predict the risk of the diabetic cardiomyopathy, resources are allocated according to a prediction result, and waste of medical resources is reduced.

The invention relates to the field of medicine synthesis, and discloses a GCG-GLP-1 dual agonist compound. The GCG-GLP-1 dual-agonist compound provided by the invention is used for preparing a pharmaceutical composition for treating diseases, and the application of the pharmaceutical composition in preparing a medicine for treating at least one of the following diseases, the diseases include type II diabetes mellitus, impaired glucose tolerance, type I diabetes mellitus, obesity, hypertension, metabolic syndrome, dyslipidemia, cognitive impairment, atherosclerosis, myocardial infarction, coronary heart disease, cardiovascular disease, stroke, inflammatory bowel syndrome and / or dyspepsia or gastric ulcer, hepatic fibrosis disease and pulmonary fibrosis disease.

The invention relates to the field of medicine synthesis, and discloses a GLP-1 / GIP / GCG tri-agonist compound. The GLP-1 / GIP / GCG three-agonist compound is used for preparing a medicine composition for treating diseases, and the application of the medicine composition in preparing a medicine for treating at least one of the following diseases, namely, the GLP-1 / GIP / GCG three-agonist compound, and the GLP-1 / GIP / GCG three-agonist compound. The diseases include type II diabetes mellitus, impaired glucose tolerance, type I diabetes mellitus, obesity, hypertension, metabolic syndrome, dyslipidemia, cognitive impairment, atherosclerosis, myocardial infarction, coronary heart disease, cardiovascular disease, stroke, inflammatory bowel syndrome and / or dyspepsia or gastric ulcer, hepatic fibrosis disease and pulmonary fibrosis disease.

The invention relates to the field of medicine synthesis, and discloses a GLP-1 / GIP / GCG tri-agonist compound. The GLP-1 / GIP / GCG three-agonist compound is used for preparing a medicine composition for treating diseases, and the application of the medicine composition in preparing a medicine for treating at least one of the following diseases, namely, the GLP-1 / GIP / GCG three-agonist compound, and the GLP-1 / GIP / GCG three-agonist compound. The diseases include type II diabetes mellitus, impaired glucose tolerance, type I diabetes mellitus, obesity, hypertension, metabolic syndrome, dyslipidemia, cognitive impairment, atherosclerosis, myocardial infarction, coronary heart disease, cardiovascular disease, stroke, inflammatory bowel syndrome and / or dyspepsia or gastric ulcer, hepatic fibrosis disease and pulmonary fibrosis disease.

The invention discloses a preparation method and application of a novel glycoside component in eupatorium chinense. The compound is separated from an eupatorium chinense extract. The eupatorium chinense root extract is separated by using an extraction method, macroporous adsorption resin impurity removal, HW-40F gel column chromatography, high performance liquid chromatography and other methods to obtain a new glycoside compound. The inhibitory activity of the separated compound on diabetes related targets alpha-glucosidase and protein tyrosine phosphatase 1B (PTP1B) is tested, the experimental result shows that the compound has good inhibitory activity on two enzymes, and the molecular docking experiment also shows that the compound has good inhibitory activity on the two enzymes. The compound has good binding energy with two target protein alpha-glucosidase and protein tyrosine phosphatase 1B. Therefore, the compound can be used for preparing medicines for preventing, delaying or treating alpha-glucosidase or PTP1B-mediated diseases, especially type II diabetes and obesity, or can be used as a lead compound of the medicines.

The invention discloses a method for researching the influence of lower limb movement on the blood sugar of a type II diabetes patient, and relates to the technical field of medical health. Comprising the following steps: S1, screening research objects: selecting patients diagnosed as T2DM; s2, CPET evaluation: performing CPET on the patient by using a professional cardiopulmonary exercise test system, and measuring cardiopulmonary function indexes of the patient, including anaerobic threshold and maximum oxygen uptake; individualized exercise intensity is formulated according to the data; s3, diet control: ensuring that the patient takes standardized breakfast before testing so as to reduce the influence of food intake on blood sugar fluctuation. According to the method, the patient is assessed in detail through the cardiopulmonary exercise test, the oxygen-free threshold, the maximum oxygen uptake and other key indexes are obtained, and the exercise intensity and mode meeting individual requirements can be formulated; according to blood glucose data and cardiopulmonary function indexes monitored in real time, the exercise scheme is dynamically adjusted, and reliability and safety are improved.

The invention provides an FTO (fluorine-doped tin oxide) inhibitor as well as a preparation method and application thereof, and particularly discloses 2-(substituted benzene miscellaneous group) aromatic formic acid as shown in the following general formula (I), derivative compounds of the 2-(substituted benzene miscellaneous group) aromatic formic acid and pharmaceutically acceptable salts, hydrates or solvates of the 2-(substituted benzene miscellaneous group) aromatic formic acid, which can be used as an FTO target inhibitor for treating diseases related to the FTO target. The compound can be used for treating human myelodysplastic syndrome, such as leukemia, lymphoma, myelodysplastic syndrome, obesity, metablic syndrome (MS), type II diabetes (Type 2 diabetes, T2D), Alzheimer's disease, breast cancer, kidney cancer, colorectal cancer, pancreatic cancer, liver cancer, small cell lung cancer, human bone marrow rhabdomyoma, pancreatic cancer, malignant glioblast brain tumor and the like. # imgabs0 #

The invention relates to the field of medicine synthesis, and discloses a GLP-1 / GCG dual-agonist compound. The GLP-1 / GCG dual-agonist compound provided by the invention is used for preparing a pharmaceutical composition for treating diseases, and application of the pharmaceutical composition in preparation of a medicine for treating at least one of the following diseases, the diseases include type II diabetes mellitus, impaired glucose tolerance, type I diabetes mellitus, obesity, hypertension, metabolic syndrome, dyslipidemia, cognitive impairment, atherosclerosis, myocardial infarction, coronary heart disease, cardiovascular disease, stroke, inflammatory bowel syndrome and / or dyspepsia or gastric ulcer, hepatic fibrosis disease and pulmonary fibrosis disease.

The invention relates to an exosome fusion liver targeting liposome drug delivery system as well as a preparation method and application thereof, and belongs to the field of high polymer material science and pharmaceutical preparations. The invention discloses an exosome-fused liver-targeted liposome drug delivery system, which combines high-concentration PEG8000 and Nycodenz in a breakthrough manner, synergistically improves the fusion efficiency of exosome and liposome, and forms bionic vesicles with uniform size and high drug loading capacity. The exosome not only can exert the anti-inflammatory and anti-oxidation characteristics, but also plays a role in resisting a severe gastrointestinal environment and crossing a biological barrier. In addition, liposome is modified by cholic acid derivatives through EDC / NHS mediated amidation reaction, precise targeting of the liver is achieved, and the liposome is fully accumulated in the liver. The effects synergistically realize the treatment of type II diabetes and non-alcoholic steatohepatitis.

The invention provides a lactic acid bacteria composition for adjuvant treatment of diabetes, a compound lactic acid bacteria probiotic agent and application, and belongs to the technical field of functional microorganisms. The lactic acid bacteria composition provided by the invention is obtained by compounding eight specific lactic acid bacteria strains, has the effects of reducing blood sugar, blood fat and insulin level for people with high blood sugar and diabetics, and also has the effect of regulating gastrointestinal tract disorder. Therefore, the compound lactic acid bacteria probiotic agent prepared on the basis of the lactic acid bacteria composition has a good blood sugar control effect on people with high blood sugar and patients with type II diabetes mellitus. Meanwhile, the compound lactic acid bacteria probiotic agent has no side effect, and the purpose of safe prevention and treatment can be achieved.

The invention belongs to the technical field of microorganisms, and particularly relates to a lactobacillus mucus fermentation TY-M26 and application of the lactobacillus mucus fermentation TY-M26, and the preservation number of the lactobacillus mucus fermentation TY-M26 is CGMCC (China General Microbiological Culture Collection Center) No. 32238. The lactobacillus mucilaginosus TY-M26 has high inhibitory activity on alpha-glucosidase activity, and animal experiments prove that the lactobacillus mucilaginosus TY-M26 can significantly relieve diabetes characteristics of mice with type II diabetes, significantly reduce fasting blood-glucose level, significantly improve insulin resistance and serum insulin level, significantly reduce serum Glu level and serum TG level, and can be used for preparing medicines for treating diabetes mellitus. The pathological injury of pancreatic tissues is obviously improved; the lactobacillus mucilaginosus TY-M26 has the advantages that the lactobacillus mucilaginosus TY-M26 can be used for preparing the lactobacillus mucilaginosus TY-M26, the serum ALT level and the serum AST level can be obviously reduced, the pathological injury of liver tissues can be obviously improved, a certain protection effect on the liver is achieved, and the lactobacillus

A method for modulating metabolism is provided which includes the step of providing a consumable composition including an extract containing a compound of Formula I to a subject in need thereof thereby modulating the subject's metabolism and addressing the underlying pathogenesis of metabolic disorders, such as nonalcoholic fatty liver disease, nonalcoholic steatohepatitis and type II diabetes mellitus.

The embodiment of the invention discloses a method for acquiring face spectral information of a type II diabetes patient; the face spectrum information is input into a pre-constructed model, corresponding traditional Chinese medicine constitution information is output, the traditional Chinese medicine constitution information comprises mild constitution, yin deficiency constitution, yang deficiency constitution, phlegm-dampness constitution, blood stasis constitution, qi deficiency constitution, qi depression constitution, specific intrinsic constitution and damp-heat constitution, and the pre-trained model is a model constructed based on a partial least square method. The purpose of non-contact judgment of the traditional Chinese medicine constitution information of the type II diabetes mellitus is achieved.

The invention discloses a preparation method of a fermented soybean extract-containing composition for controlling blood sugar of type II diabetes people, and particularly relates to the technical field of blood sugar control, and the preparation method comprises the following steps: preparing raw materials, preparing a fermented soybean extract, mixing the materials, applying a low-temperature crushing technology, and detecting alpha-glucosidase inhibitory activity of the fermented soybean extract. A novel packaging material is adopted for packaging. Through the synergistic effect of various natural extracts, such as the fermented soybean extract for inhibiting digestive enzymes, the white kidney bean extract and the mulberry leaf extract for regulating blood sugar and the like, the blood sugar level of a patient is effectively reduced, and the formation mechanism of converting starch food into saccharides and the formation mechanism of fat can be quickly and effectively controlled; the traditional Chinese medicine composition has the effects of quickly regulating blood sugar, controlling body weight, improving organism immunity, regulating blood fat and the like, and reduces the pain of various adverse reactions caused by medicine taking of type II diabetes patients, and the preparation method brings new hope to the type II diabetes patients and is expected to play an important role in diabetes prevention and treatment.

The invention discloses a pioglitazone hydrochloride microneedle drug delivery system for treating type II diabetes and a preparation method of the pioglitazone hydrochloride microneedle drug delivery system. The pioglitazone hydrochloride microneedle drug delivery system comprises a pioglitazone hydrochloride hydrogel microneedle patch, an electric moistening gel patch and intelligent wearable equipment, the pioglitazone hydrochloride hydrogel microneedle comprises the following components in percentage by mass: 0.5%-2.0% of pioglitazone hydrochloride, 12%-17% of a pioglitazone hydrochloride microneedle skeleton, 1%-2% of an auxiliary skeleton material, 0%-0.5% of a conductive material, 10%-20% of a glucose response material, 0.5%-1% of a fluorescent material and 57.5%-76% of ultrapure water, the electrowetting gel patch is divided into an inner layer and an outer layer, the inner layer is prepared from, by weight, 2.0%-5.0% of a gel framework material, 0%-0.5% of a conductive material and 94.5%-98% of ultrapure water, and the outer layer is prepared from, by weight, 3%-12% of a matrix, 0.1%-0.5% of a cross-linking agent, 20%-60% of a humectant, 1%-5% of a tackifier, 2%-6% of an excipient, 0.2%-0.8% of a cross-linking regulator, 0.02%-0.08% of a complexing agent and 22%-58% of water. The intelligent wearable device is used for monitoring the blood glucose of the human body, when the blood glucose level exceeds a preset threshold value, drug release is accurately controlled through the drug delivery module, and the treatment efficiency and safety are improved.

The application discloses application of Xintong preparation in preparation of a medicine for treating diabetes and a preparation method thereof, and belongs to the field of traditional Chinese medicines. The Xintong preparation is prepared from 13 raw medicinal materials of Huangqi, Gegen, Danshen, Dangshen, Maidong, Heshouwu, Yinyanghuo, Dangui, Zaokesheng, Haizao, Kelp, Muli and Zhishi, has the effects of benefiting qi and activating blood, reducing phlegm and dredging collaterals. Pharmacodynamic experiments show that the Xintong preparation has the effect of reducing blood sugar, can effectively improve the physical conditions of polydipsia, polyphagia, polyuria and emaciation and lack of strength of an animal model of diabetes, significantly reduces the fasting blood sugar and serum insulin level, improves the oral glucose tolerance, has a definite treatment effect on type II diabetes, and expands the clinical application range of the Xintong preparation, and has a wide market application prospect.

The invention relates to application of lactobacillus acidophilus LA85 in preparation of a product with a blood sugar reducing effect. The brand new application of the lactobacillus acidophilus LA85 strain is developed, namely the lactobacillus acidophilus LA85 strain is used for inhibiting alpha-glucosidase, reducing blood sugar and improving diabetes mellitus, and tests prove that the food intake, the water intake and the urine volume of a mouse with type II diabetes mellitus can be effectively controlled after intervention of the LA85 strain, and the weight value of the mouse is stabilized; the glucose absorption and metabolism capability of diabetic mice is effectively improved, and continuous damage of pancreatic beta cell functions is retarded; the blood lipid level disorder state of the mouse with the type II diabetes mellitus is improved; the inflammation level of a mouse body with type II diabetes mellitus is reduced, and the immunity is improved; and a very good improvement and recovery effect is achieved on abundance and diversity reduction of intestinal flora of the type II diabetes mellitus mice.

The invention belongs to the technical field of medicines, and relates to an application of a pharmaceutical composition in preparation of medicines for preventing and / or treating type II diabetes mellitus. The invention provides an application of a pharmaceutical composition in preparation of a medicine for preventing and / or treating type II diabetes mellitus. The pharmaceutical composition comprises the following components: ginsenoside Rk1, ginsenoside Rg5, ginsenoside Rg3, ginsenoside Rh4, ginsenoside Rk3, a ginseng ethanol-water extract and a pharmaceutically acceptable carrier. The pharmaceutical composition component provided by the invention can effectively reduce blood sugar and / or reduce the glycosylated hemoglobin level, and prevent and / or treat type II diabetes mellitus.

In one embodiment, the present invention provides a compound of the formula: # imgabs0 # or a pharmaceutically acceptable salt thereof, as well as methods of using such compounds in the treatment of type 2 diabetes mellitus.

Provided herein are pharmaceutical formulations comprising glucokinase activator, or a prodrug, or a pharmaceutically acceptable salt, an isotope labeled analogue, a crystalline form, a hydrate, a solvate, or a diastereomeric or enantiomeric form thereof and the use thereof for treating diseases; the pharmaceutical formulations are in the form of immediate-release formulations, extended-release formulations, or combination of immediate-release formulation and extended-release formulations. The pharmaceutical formulations achieved once-a-day therapy for some diseases, in particular, type II Diabetes Mellitus with obesity. The pharmaceutical formulations exhibit sustained 24 hours of glucose-lowering effects. The pharmaceutical formulations also achieved lower Cmax, extended T1 / 2 as well as maintained similar bioavailability and increased MRT compared with commercial Dorzagliatin tablet, enhanced the pharmacology effect of restoring the glucose stimulated GLP-1 secretion in diabetes with obesity.

Provided herein are methods for improving glycemic control in a human patient, methods for treating, preventing or reducing overweight or obesity and related co-conditions, and methods for treating or preventing type II diabetes mellitus by administering a polypeptide to the patient, the polypeptide comprises a fibronectin type III tenth (10Fn3) domain that binds to a myostatin. In some embodiments, the polypeptides are administered according to a specific clinical dosing regimen (e.g., at a specific dose and according to a specific time interval) (or for administration according to the regimen).

The invention provides biological nano composite hydrogel as well as a preparation method and application thereof, and the preparation method of the biological nano composite hydrogel comprises the following steps: dissolving VVPS and beta-CD in a NaOH aqueous solution, heating to 60-63 DEG C, and stirring for more than 30 minutes until the VVPS and the beta-CD are completely dissolved; slowly adding PEGDGE into the solution, continuously stirring until the cross-linking agent is dissolved, raising the temperature to 65 DEG C or above, and reacting for 4 hours or above to form hydrogel; and performing swelling treatment on the hydrogel, drying, soaking in an ethanol water solution containing capsaicin for more than 48 hours, filtering, and performing freeze drying. The biological nano composite hydrogel prepared by the preparation method disclosed by the invention has good application in delivery of capsaicin and alleviation of type II diabetes mellitus.

To provide a beverage composition for improving cognitive function, managing and / or treating type II diabetes, reducing postprandial glycemia, and promoting weight loss.SOLUTION: A beverage composition comprising at least 600 mg polyphenols and at least 1 g of fiber, the beverage composition being less than 100 Kcal, is provided.SELECTED DRAWING: None

The invention relates to the technical field of grain processing, and discloses wheat flour, a preparation method thereof and fine dried noodles, the grain granularity of the wheat flour is 68-91 [mu] m, the wheat flour is prepared by rolling wheat flour as a raw material through a smooth roller, and compared with refined wheat flour added with bran, the wheat flour is pure white in color and higher in quality, and compared with the refined wheat flour, the wheat flour has the advantages that the grain size is small; the content of fat and dietary fibers is remarkably increased, the content of damaged starch is remarkably reduced, the cooking loss rate and protein digestibility of fine dried noodles prepared from the wheat flour are remarkably reduced, and the fine dried noodles prepared from the wheat flour are better in taste, high in chewiness and low in cooking loss rate and protein digestibility. The risk that obesity and type II diabetes mellitus are increased due to long-term consumption of the refined wheat flour can be avoided.

Disclosed in the invention are a type of compounds having activity of activating 5′-adenosine monophosphate-activated protein kinase (AMPK), a method for the preparation thereof, a pharmaceutical composition comprising the same, and use of these compounds in the manufacture of a medicament for reducing fatty acid synthesis, for inhibiting triglyceride and cholesterol synthesis, for preventing and / or treating obesity and type II diabetes, for preventing and / or treating tumor, for preventing and / or treating Parkinson's disease, for preventing and / or treating Alzheimer's disease or for prolonging the lifespan of mammals:

The invention belongs to the technical field of polypeptide preparation and biological medicine, and particularly relates to a preparation method of Jingzhaotoxin polypeptide IX (JZTX-IX) and application of Jingzhaotoxin polypeptide IX in treatment of diabetes mellitus. A chilobrachys jingzhao toxin polypeptide IX coding gene, a 6 * His tag nucleotide sequence, a thrombin restriction enzyme cutting site nucleotide sequence and an MBP hydrotropy tag nucleotide sequence are connected to a prokaryotic expression vector for prokaryotic expression, and the expressed polypeptide is purified to obtain the chilobrachys jingzhao toxin polypeptide IX protein. The target polypeptide with high purity, complete disulfide bond folding and uniform conformation is obtained, so that the high purity and biological activity of the target polypeptide are ensured. On the basis, the treatment activity of the JZTX-IX on diabetes mellitus especially type II diabetes mellitus is found and verified, and the JZTX-IX can remarkably reduce fasting blood glucose of mice with the type II diabetes mellitus, improve glucose tolerance and insulin sensitivity, relieve polydipsia and polyuria symptoms and promote insulin secretion and islet cell proliferation.